E-LIB Suche - Ergebnisse für: Scarfò, L.

1

EE82 A Cost-Utility Analysis of the MyPal eHealth Applicati..:

Naoum, P. ; Athanasakis, K. ; Radova, L....
Value in Health. 26 (2023) 12 - p. S66 , 2023

Link: https://doi.org/10.1016/..

2

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PH..:

Frustaci, A. M. ; Montillo, M. ; Rossi, D....
Hematological Oncology. 41 (2023) S2 - p. 62-63 , 2023

Link: https://doi.org/10.1002/..

3

P597: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY IN ..:

Bordini, J. ; Lenzi, C. ; Toscani, L....
HemaSphere. 6 (2022) - p. 496-497 , 2022

Link: https://doi.org/10.1097/..

4

P593: MULTIDIMENSIONAL ANALYSIS OF THE B CELL RECEPTOR OFFE..:

Agathangelidis, A. ; Galigalidou, C. ; Iatrou, A....
HemaSphere. 6 (2022) - p. 492-493 , 2022

Link: https://doi.org/10.1097/..

5

PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS..:

Vrontaras, N. ; Kyrou, D. ; Kapetanakis, A....
HemaSphere. 6 (2022) - p. 2231-2232 , 2022

Link: https://doi.org/10.1097/..

6

PB2349: LESSONS LEARNED FROM THE MYPAL DIGITAL HEALTH INTER..:

Karamanidou, C. ; Scarfò, L. ; Doubek, M....
HemaSphere. 6 (2022) - p. 2218-2219 , 2022

Link: https://doi.org/10.1097/..

7

S144: IMMUNE RESTORATION AND SYNERGISTIC ACTIVITY WITH FIRS..:

Solman, I. ; Singh Mali, R. ; Scarfo, L....
HemaSphere. 6 (2022) - p. 45-46 , 2022

Link: https://doi.org/10.1097/..

8

MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CL..:

Frustaci, A. M. ; Tedeschi, A. ; Zinzani, P. L....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT..:

Visentin, A. ; Mauro, F. R. ; Cibien, F....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

10

ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS ..:

Terzi di Bergamo, L ; Forestieri, G ; Loh, J. W...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RI..:

Condoluci, A. ; Terzi‐di‐Bergamo, L. ; Forestieri, G....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

Refractory and 17p-deleted chronic lymphocytic leukemia: im..:

Farina, L. ; Barretta, F. ; Scarfò, L....
Biology of Blood and Marrow Transplantation. 26 (2020) 10 - p. e256-e262 , 2020

Link: https://doi.org/10.1016/..

13

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN ..:

Zinzani, P. ; Samaniego, F. ; Jurczak, W....
Hematological Oncology. 37 (2019) S2 - p. 182-183 , 2019

Link: https://doi.org/10.1002/..

14

SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHI..:

Carlo‐Stella, C. ; Barde, P. ; Delarue, R....
Hematological Oncology. 35 (2017) S2 - p. 263-263 , 2017

Link: https://doi.org/10.1002/..

15

A MRD‐GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO V..:

Ghia, P. ; Scarfò, L. ; Coscia, M....
Hematological Oncology. 35 (2017) S2 - p. 426-427 , 2017

Link: https://doi.org/10.1002/..